c-RAF ablation induces regression of advanced Kras/Trp53 mutant lung adenocarcinomas by a mechanism independent of MAPK signaling

K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions

Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557 · see citing works

Drugging the undruggable RAS: Mission Possible?

Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997 · see citing works

Non-small-cell lung cancers: a heterogeneous set of diseases

Chen, Z., Brainson, C. F., Hammerman, P. S., Kim, C. F., & Wong, K. (2014) · Nature reviews. Cancer · doi:10.1038/nrc3775 · Cited by 1,936 · see citing works

Targeting RAS–ERK signalling in cancer: promises and challenges

Samatar, A. A., & Poulikakos, P. I. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4281 · Cited by 1,163 · see citing works

Targeting the mitogen-activated protein kinase cascade to treat cancer

Sebolt, J. S., & Herrera, R. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1503 · Cited by 1,103 · see citing works

Deletion of the Developmentally Essential Gene ATR in Adult Mice Leads to Age-Related Phenotypes and Stem Cell Loss

Ruzankina, Y., Pinzon‐Guzman, C., Asare, A., Ong, T., Pontano, L. L., Cotsarelis, G., Zediak, V. P., Velez, M., Bhandoola, A., & Brown, E. J. (2007) · Cell stem cell · doi:10.1016/j.stem.2007.03.002 · Cited by 780 · see citing works

RAS Interaction with PI3K: More Than Just Another Effector Pathway

Castellano, E., & Downward, J. (2011) · Genes & Cancer · doi:10.1177/1947601911408079 · Cited by 762 · see citing works

Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context

Guerra, C. E., Mijimolle, N., Dhawahir, A., Dubus, P. R., Barradas, M., Serrano, M., Campuzano, V., & Barbacid, M. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00191-0 · Cited by 566 · see citing works

The Differential Effects of Mutant <i>p53</i> Alleles on Advanced Murine Lung Cancer

Jackson, E. L., Olive, K. P., Tuveson, D. A., Bronson, R., Crowley, D., Brown, M., & Jacks, T. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2193 · Cited by 553 · see citing works

Expression of tumour-specific antigens underlies cancer immunoediting

DuPage, M. J. P., Mazumdar, C., Schmidt, L., Cheung, A. F., & Jacks, T. (2012) · Nature · doi:10.1038/nature10803 · Cited by 529 · see citing works

A Synthetic Lethal Interaction between K-Ras Oncogenes and Cdk4 Unveils a Therapeutic Strategy for Non-small Cell Lung Carcinoma

Puyol, M., Martín, A., Dubus, P., Mulero, F., Pizcueta, P., Khan, G., Guerra, C., Santamaría, D., & Barbacid, M. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.025 · Cited by 415 · see citing works

Improved properties of FLP recombinase evolved by cycling mutagenesis

Buchholz, F., Angrand, P., & Stewart, A. F. (1998) · Nature Biotechnology · doi:10.1038/nbt0798-657 · Cited by 404 · see citing works

Raf Family Kinases: Old Dogs Have Learned New Tricks

Matallanas, D., Birtwistle, M. R., Romano, D., Zebisch, A., Rauch, J., von Kriegsheim, A., & Kölch, W. (2011) · Genes & Cancer · doi:10.1177/1947601911407323 · Cited by 383 · see citing works

Diagnostic Efficacy of PET-FDG Imaging in Solitary Pulmonary Nodules

Dewan, N. A., Gupta, N. C., Redepenning, L. S., Phalen, J. J., & Frick, M. P. (1993) · CHEST Journal · doi:10.1378/chest.104.4.997 · Cited by 327 · see citing works

Embryonic lethality and fetal liver apoptosis in mice lacking the c‐raf‐1 gene

Mikula, M., Schreiber, M., Husak, Z., Kučerová, L., Rüth, J., Wieser, R., Zatloukal, K., Beug, H., Wagner, E. F., & Baccarini, M. (2001) · The EMBO Journal · doi:10.1093/emboj/20.8.1952 · Cited by 311 · see citing works

MEK kinase activity is not necessary for Raf‐1 function

Hüser, M., Luckett, J., Chiloeches, A., Mercer, K., Iwobi, M., Giblett, S., Sun, X., Brown, J., Marais, R., & Pritchard, C. A. (2001) · The EMBO Journal · doi:10.1093/emboj/20.8.1940 · Cited by 310 · see citing works

c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma

Blasco, R. B., Francoz, S., Santamaría, D., Cañamero, M., Dubus, P., Charron, J., Baccarini, M., & Barbacid, M. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.04.002 · Cited by 302 · see citing works

Endothelial apoptosis in Braf-deficient mice

Wojnowski, L., Zimmer, A. M., Beck, T. W., Hahn, H., Bernal, R. A., Rapp, U. R., & Zimmer, A. (1997) · Nature Genetics · doi:10.1038/ng0797-293 · Cited by 299 · see citing works

Requirement for Interaction of PI3-Kinase p110α with RAS in Lung Tumor Maintenance

Castellano, E., Sheridan, C., Thin, M. Z., Nye, E. L., Spencer‐Dene, B., Diefenbacher, M. E., Moore, C., Kumar, M. S., Murillo, M. M., Gronroos, E. C., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.09.012 · Cited by 184 · see citing works

C-Raf Is Required for the Initiation of Lung Cancer by K-RasG12D

Karreth, F. A., Frese, K. K., DeNicola, G. M., Baccarini, M., & Tuveson, D. A. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-10-0044 · Cited by 149 · see citing works

Targets of Raf in tumorigenesis

Niault, T., & Baccarini, M. (2010) · Carcinogenesis · doi:10.1093/carcin/bgp337 · Cited by 132 · see citing works

Raf-1 Addiction in Ras-Induced Skin Carcinogenesis

Ehrenreiter, K., Kern, F., Velamoor, V., Meissl, K., Galabova‐Kovacs, G., Sibilia, M. C., & Baccarini, M. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.06.008 · Cited by 103 · see citing works

Genetically engineered mouse models of cancer reveal new insights about the antitumor immune response

DuPage, M. J. P., & Jacks, T. (2013) · Current Opinion in Immunology · doi:10.1016/j.coi.2013.02.005 · Cited by 91 · see citing works

Forebrain-specific knockout of B-raf kinase leads to deficits in hippocampal long-term potentiation, learning, and memory

Chen, A. P., Ohno, M., Giese, K.-P., Kühn, R., Chen, R. L., & Silva, A. J. (2005) · Journal of Neuroscience Research · doi:10.1002/jnr.20703 · Cited by 75 · see citing works

A FRT-flankedp53mouse to generate primary tumors with Flp recombinase

Lee, C., Moding, E. J., Huang, X., Li, Y., Woodlief, L. Z., Rodrigues, R. C., Ma, Y., & Kirsch, D. G. (2011) · Disease Models & Mechanisms · doi:10.1242/dmm.009084 · Cited by 69 · see citing works

Chemical Inducers of Targeted Protein Degradation

Raina, K., & Crews, C. M. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.r109.078105 · Cited by 64 · see citing works

Protective Role of Raf-1 in Salmonella-Induced Macrophage Apoptosis

Jesenberger, V., Procyk, K. J., Rüth, J., Schreiber, M., Theussl, H., Wagner, E. F., & Baccarini, M. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.3.353 · Cited by 63 · see citing works

Prognostic Impact of [18F]Fluorothymidine and [18F]Fluoro-D-Glucose Baseline Uptakes in Patients with Lung Cancer Treated First-Line with Erlotinib

Scheffler, M., Zander, T., Nogová, L., Kobe, C., Kahraman, D., Dietlein, M., Papachristou, I., Heukamp, L. C., Büttner, R., Boellaard, R., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053081 · Cited by 41 · see citing works

KRASG12D expression in lung-resident myeloid cells promotes pulmonary LCH-like neoplasm sensitive to statin treatment

Kamata, T., Giblett, S. M., & Pritchard, C. A. (2017) · Blood · doi:10.1182/blood-2017-02-770149 · Cited by 17 · see citing works

KRAS Mutation: From Undruggable to Druggable in Cancer

Huang, L., Guo, Z., Wang, F., & Fu, L. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00780-4 · Cited by 1,127 · see citing works

RAS-targeted therapies: is the undruggable drugged?

Moore, A. R., Rosenberg, S. C., McCormick, F., & Malek, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0068-6 · Cited by 1,103 · see citing works

Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy

Degirmenci, U., Wang, M., & Hu, J. (2020) · Cells · doi:10.3390/cells9010198 · Cited by 541 · see citing works

Targeting the MAPK pathway in KRAS-driven tumors

Drosten, M., & Barbacid, M. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.013 · Cited by 512 · see citing works

Therapeutic strategies to target RAS-mutant cancers

Ryan, M. B., & Corcoran, R. B. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0105-0 · Cited by 420 · see citing works

Lung Cancers: Molecular Characterization, Clonal Heterogeneity and Evolution, and Cancer Stem Cells

Testa, U., Castelli, G., & Pelosi, E. (2018) · Cancers · doi:10.3390/cancers10080248 · Cited by 406 · see citing works

Clearance of senescent macrophages ameliorates tumorigenesis in KRAS-driven lung cancer

Haston, S., Gonzalez-Gualda, E., Morsli, S., Ge, J., Reen, V., Calderwood, A., Moutsopoulos, I., Panousopoulos, L., Deletic, P., Carreno, G., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.05.004 · Cited by 251 · see citing works

Emerging strategies to target RAS signaling in human cancer therapy

Chen, K., Zhang, Y., Qian, L. M., & Wang, P. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01127-w · Cited by 231 · see citing works

ADAM17 selectively activates the IL‐6 trans‐signaling/ERK MAPK axis in KRAS‐addicted lung cancer

Saad, M. I., Alhayyani, S., McLeod, L., Yu, L., Alanazi, M. A., Deswaerte, V., Tang, K., Jardé, T., Smith, J. A., Prodanovic, Z., et al. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201809976 · Cited by 135 · see citing works

Targeting KRAS Mutant Non-Small-Cell Lung Cancer: Past, Present and Future

Uras, I. Z., Moll, H. P., & Casanova, E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124325 · Cited by 134 · see citing works

New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness

Yang, H., Liang, S.-Q., Schmid, R. A., & Peng, R.-W. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00953 · Cited by 129 · see citing works

MAP kinase and autophagy pathways cooperate to maintain RAS mutant cancer cell survival

Lee, C.-S., Lee, L. C., Yuan, T. L., Chakka, S., Fellmann, C., Lowe, S. W., Caplen, N. J., McCormick, F., & Luo, J. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1817494116 · Cited by 126 · see citing works

Complete regression of advanced pancreatic ductal adenocarcinomas upon combined inhibition of EGFR and C-RAF

Blasco, M. T., Navas, C., Martín-Serrano, G., Graña-Castro, O., Lechuga, C. G., Martín-Díaz, L., Djurec, M., Li, J., Morales-Cacho, L., Esteban-Burgos, L., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.03.002 · Cited by 115 · see citing works

Erianin suppresses constitutive activation of MAPK signaling pathway by inhibition of CRAF and MEK1/2

Wang, P., Jia, X., Lu, B., Huang, H., Liu, J., Liu, X., Wu, Q., Hu, Y., Li, P., Wei, H., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01329-3 · Cited by 96 · see citing works

Targeting small GTPases: emerging grasps on previously untamable targets, pioneered by KRAS

Yin, G., Huang, J., Petela, J., Jiang, H., Zhang, Y., Gong, S., Wu, J., Liu, B., Shi, J., & Gao, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01441-4 · Cited by 87 · see citing works

Statin-mediated inhibition of RAS prenylation activates ER stress to enhance the immunogenicity of KRAS mutant cancer

Nam, G.-H., Kwon, M., Jung, H., Ko, E., Kim, S. A., Choi, Y., Song, S. J., Kim, S., Lee, Y., Kim, G. B., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002474 · Cited by 82 · see citing works

The ERK mitogen-activated protein kinase signaling network: the final frontier in RAS signal transduction

Klomp, J. E., Klomp, J. A., & Der, C. J. (2021) · Biochemical Society Transactions · doi:10.1042/bst20200507 · Cited by 83 · see citing works

SHOC2 phosphatase-dependent RAF dimerization mediates resistance to MEK inhibition in RAS-mutant cancers

Jones, G. G., del Río, I. B., Sarı, S., Sekerim, A., Young, L. C., Hartig, N., Zubiaur, I. A., El-Bahrawy, M. A., Hynds, R. E., Lei, W., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10367-x · Cited by 77 · see citing works

Extracellular‐signal‐regulated kinase/mitogen‐activated protein kinase signaling as a target for cancer therapy: an updated review

Najafi, M., Ahmadi, A., & Mortezaee, K. (2019) · Cell Biology International · doi:10.1002/cbin.11187 · Cited by 78 · see citing works

Comprehensive Analysis of ERK1/2 Substrates for Potential Combination Immunotherapies

Yang, L., Zheng, L., Chng, W. J., & Ding, J. L. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.09.005 · Cited by 76 · see citing works

Pharmacological Induction of RAS-GTP Confers RAF Inhibitor Sensitivity in KRAS Mutant Tumors

Yen, I., Shanahan, F., Merchant, M. A., Orr, C., Hunsaker, T., Durk, M. R., La, H., Zhang, X., Martin, S. E., Lin, E., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.09.002 · Cited by 78 · see citing works

Structure of the RAF1-HSP90-CDC37 complex reveals the basis of RAF1 regulation

García‐Alonso, S., Mesa, P., Ovejero, L. D. L. P., Aizpurua, G., Lechuga, C. G., Zarzuela, E., Santiveri, C. M., Sanclemente, M., Muñoz, J., Musteanu, M., et al. (2022) · Molecular Cell · doi:10.1016/j.molcel.2022.08.012 · Cited by 72 · see citing works

Impact of context-dependent autophagy states on tumor progression

Assi, M., & Kimmelman, A. C. (2023) · Nature Cancer · doi:10.1038/s43018-023-00546-7 · Cited by 75 · see citing works

Drugging the Undruggable: Advances on RAS Targeting in Cancer

Molina‐Arcas, M., Samani, A., & Downward, J. (2021) · Genes · doi:10.3390/genes12060899 · Cited by 73 · see citing works

Protein–Protein Interactions: Emerging Oncotargets in the RAS-ERK Pathway

García-Gómez, R., Bustelo, X. R., & Crespo, P. (2018) · Trends in Cancer · doi:10.1016/j.trecan.2018.07.002 · Cited by 72 · see citing works

Accessory proteins of the RAS-MAPK pathway: moving from the side line to the front line

Pudewell, S., Wittich, C., Jasemi, N. S. K., Bazgir, F., & Ahmadian, M. R. (2021) · Communications Biology · doi:10.1038/s42003-021-02149-3 · Cited by 72 · see citing works

Signaling from RAS to RAF: The Molecules and Their Mechanisms

Jeon, H., Tkacik, E., & Eck, M. J. (2024) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-052521-040754 · Cited by 64 · see citing works

Transforming targeted cancer therapy with PROTACs: A forward-looking perspective

Farnaby, W., Koegl, M., McConnell, D. B., & Ciulli, A. (2021) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2021.02.009 · Cited by 65 · see citing works

40 Years of RAS—A Historic Overview

Fernández‐Medarde, A., Rivas, J. D. L., & Santos, E. (2021) · Genes · doi:10.3390/genes12050681 · Cited by 53 · see citing works

Kras oncogene ablation prevents resistance in advanced lung adenocarcinomas

Salmón, M., Álvarez-Díaz, R., Fustero-Torre, C., Brehey, O., Lechuga, C. G., Sanclemente, M., Fernández-García, F., López-García, A., Martín-Guijarro, M. C., Rodríguez-Perales, S., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci164413 · Cited by 52 · see citing works

Confounding Factors in Targeted Degradation of Short-Lived Proteins

Vetma, V., Perez, L. C., Eliaš, J., Stingu, A., Kombara, A., Gmaschitz, T., Braun, N., Ciftci, T., Dahmann, G., Diers, E., et al. (2024) · ACS Chemical Biology · doi:10.1021/acschembio.4c00152 · Cited by 53 · see citing works

Human aneuploid cells depend on the RAF/MEK/ERK pathway for overcoming increased DNA damage

Zerbib, J., Ippolito, M. R., Eliezer, Y., Feudis, G. D., Reuveni, E., Kadmon, A. S., Martin, S., Viganò, S., Leor, G., Berstler, J., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52176-x · Cited by 47 · see citing works

Onco-immunomodulatory properties of pharmacological interference with RAS-RAF-MEK-ERK pathway hyperactivation

Avery, T. Y., Köhler, N., Zeiser, R., Brummer, T., & Ruess, D. A. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.931774 · Cited by 51 · see citing works

HERC Ubiquitin Ligases in Cancer

Sala-Gaston, J., Martinez-Martinez, A., Pedrazza, L., Lorenzo‐Martín, L. F., Caloto, R., Bustelo, X. R., Ventura, F., & Rosa, J. L. (2020) · Cancers · doi:10.3390/cancers12061653 · Cited by 50 · see citing works

Targeting Glucose Metabolism Sensitizes Pancreatic Cancer to MEK Inhibition

Yan, L., Tu, B., Yao, J., Gong, J., Carugo, A., Bristow, C. A., Wang, Q., Zhu, C., Dai, B., Kang, Y., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-3792 · Cited by 48 · see citing works

Targeting KRAS mutant lung cancer: light at the end of the tunnel

Drosten, M., & Barbacid, M. (2021) · Molecular Oncology · doi:10.1002/1878-0261.13168 · Cited by 47 · see citing works

Everything Old Is New Again: Drug Repurposing Approach for Non-Small Cell Lung Cancer Targeting MAPK Signaling Pathway

Jain, A. S., Prasad, A., Pradeep, S., Dharmashekar, C., Achar, R. R., Silina, E. V., Stupin, V. A., Amachawadi, R. G. G., Prasad, S. K., Pruthvish, R., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.741326 · Cited by 50 · see citing works

CRAF dimerization with ARAF regulates KRAS-driven tumor growth

Venkatanarayan, A., Liang, J., Yen, I., Shanahan, F., Haley, B., Phu, L., Verschueren, E., Hinkle, T. B., Kan, D., Segal, E., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110351 · Cited by 45 · see citing works

Targeting CRAF kinase in anti-cancer therapy: progress and opportunities

Wang, P., Laster, K. V., Jia, X., Dong, Z., & Liu, K. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01903-x · Cited by 40 · see citing works

The role of CRAF in cancer progression: from molecular mechanisms to precision therapies

Riaud, M., Maxwell, J., Soria‐Bretones, I., Dankner, M., Li, M., & Rose, A. A. N. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-023-00650-x · Cited by 39 · see citing works

KRAS G12C-mutant driven non-small cell lung cancer (NSCLC)

Rosell, R., Codony‐Servat, J., González, J., Santarpía, M., Jain, A. S., Shivamallu, C., Wang, Y., Giménez-Capitán, A. A., Molina‐Vila, M. Á., Nilsson, J. A., et al. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104228 · Cited by 39 · see citing works

RAS degraders: The new frontier for RAS-driven cancers

Escher, T. E., & Satchell, K. J. F. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.03.017 · Cited by 35 · see citing works

RAF1 kinase activity is dispensable for KRAS/p53 mutant lung tumor progression

Sanclemente, M., Nieto, P., García‐Alonso, S., Fernández-García, F., Esteban-Burgos, L., Guerra, C. E., Drosten, M., Caleiras, E. J., Martinez-Torrecuadrada, J. L., Santamarı́a, D., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.01.008 · Cited by 34 · see citing works

KSR induces RAS‐independent MAPK pathway activation and modulates the efficacy of KRAS inhibitors

Paniagua, G., Jacob, H. K. C., Brehey, O., García‐Alonso, S., Lechuga, C. G., Pons, T., Musteanu, M., Guerra, C., Drosten, M., & Barbacid, M. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13213 · Cited by 34 · see citing works

Prodigiosin induces apoptosis and inhibits autophagy via the extracellular signal-regulated kinase pathway in K562 cells

Ji, S., Sun, R., Xu, K., Man, Z., Ji, J., Pu, Y., Yin, L., Zhang, J., & Pu, Y. (2019) · Toxicology in Vitro · doi:10.1016/j.tiv.2019.05.003 · Cited by 32 · see citing works

c-Raf in KRas Mutant Cancers: A Moving Target

McCormick, F. P. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.01.017 · Cited by 27 · see citing works

Exploiting the Anticancer, Antimicrobial and Antiviral Potential of Naphthoquinone Derivatives: Recent Advances and Future Prospects

Xiang, S., Li, Y., Khan, S. N., Zhang, W., Yuan, G., & Cui, J. (2025) · Pharmaceuticals · doi:10.3390/ph18030350 · Cited by 26 · see citing works

Cryo-EM structures of CRAF/MEK1/14-3-3 complexes in autoinhibited and open-monomer states reveal features of RAF regulation

Jang, D. M., Boxer, K., Ha, B. H., Tkacik, E., Levitz, T. S., Rawson, S. D., Metivier, R. J., Schmoker, A. M., Jeon, H., & Eck, M. J. (2025) · Nature Communications · doi:10.1038/s41467-025-63227-2 · Cited by 27 · see citing works

Role of MEK-ERK signaling mediated adhesion of glioma cells to extracellular matrix: Possible implication on migration and proliferation

Ramaswamy, P., Nanjaiah, N. D., & Borkotokey, M. (2019) · Annals of Neurosciences · doi:10.5214/ans.0972.7531.260203 · Cited by 25 · see citing works

Covalent inhibitor targets KRasG12C: A new paradigm for drugging the undruggable and challenges ahead

Li, H., Qi, W.-L., Wang, Y., & Meng, L. (2021) · Genes & Diseases · doi:10.1016/j.gendis.2021.08.011 · Cited by 25 · see citing works

RAS‐targeted cancer therapy: Advances in drugging specific mutations

Liu, C., Ye, D., Yang, H., Chen, X., Su, Z., Li, X., Ding, M., & Liu, Y. (2023) · MedComm · doi:10.1002/mco2.285 · Cited by 24 · see citing works

Tumor regression and resistance mechanisms upon CDK4 and RAF1 inactivation in KRAS/P53 mutant lung adenocarcinomas

Esteban-Burgos, L., Wang, H., Nieto, P., Zheng, J., Blanco‐Aparicio, C., Varela, C., Goméz-López, G., Fernández-García, F., Sanclemente, M., Guerra, C. E., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2002520117 · Cited by 23 · see citing works

Requirement for epithelial p38α in KRAS-driven lung tumor progression

Vitos‐Faleato, J., Real, S., Gutierrez-Prat, N., Villanueva, A., Llonch, E., Drosten, M., Barbacid, M., & Nebreda, Á. R. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1921404117 · Cited by 23 · see citing works

Selective CRAF Inhibition Elicits Transactivation

Morgan, C. W., Dale, I. L., Thomas, A. P., Hunt, J., & Chin, J. W. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.0c11958 · Cited by 21 · see citing works

KRAS4A induces metastatic lung adenocarcinomas in vivo in the absence of the KRAS4B isoform

Salmón, M., Paniagua, G., Lechuga, C. G., Fernández-García, F., Zarzuela, E., Álvarez, R., Musteanu, M., Guerra, C. E., Caleiras, E. J., Muñoz, J., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2023112118 · Cited by 19 · see citing works

Targeting the ERK mitogen-activated protein kinase cascade for the treatment of KRAS-mutant pancreatic cancer

Diehl, J. N., Hibshman, P. S., Ozkan‐Dagliyan, I., Goodwin, C. M., Howard, S. V., Cox, A. D., & Der, C. J. (2022) · Advances in cancer research · doi:10.1016/bs.acr.2021.07.008 · Cited by 18 · see citing works

Spindle cell tumour with S100 and CD 34 co‐expression showing PDZRN 3– RAF 1 rearrangement – a recently described entity

Mok, Y., Kimpo, M. S., Chen, H., Kuick, C. H., Chang, K. T. E., & Lee, V. K. M. (2019) · Histopathology · doi:10.1111/his.13841 · Cited by 18 · see citing works

Treatment resistance to platinum-based chemotherapy in lung and ovarian cancer is driven by a targetable TGFβ senescent secretome

González‐Gualda, E., Reinius, M., Macías, D., Morsli, S., Ge, J., Olan, I., Martín, J. E., Ou, H., Hartono, M., Puerto-Camacho, M. P., et al. (2026) · Nature Aging · doi:10.1038/s43587-025-01054-2 · Cited by 18 · see citing works

Targeted degradation of oncogenic KRASG12V triggers antitumor immunity in lung cancer models

Li, D., Geng, K., Yuan, H., Gu, J., Kumar, S., Olson, A. T., Kuismi, C. C., Kim, H. M., Pan, Y., Sherman, F., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci174249 · Cited by 17 · see citing works

Targeting KRAS in NSCLC: Old Failures and New Options for “Non-G12c” Patients

Jacobs, F., Cani, M., Malapelle, U., Novello, S., Napoli, V. M., & Bironzo, P. (2021) · Cancers · doi:10.3390/cancers13246332 · Cited by 17 · see citing works

Allosteric PROTACs: Expanding the Horizon of Targeted Protein Degradation

Frost, A. B., O’Connor, S., & Ciulli, A. (2026) · Journal of the American Chemical Society · doi:10.1021/jacs.5c14840 · Cited by 21 · see citing works

The sodium channel subunit SCNN1B suppresses colorectal cancer via suppression of active c-Raf and MAPK signaling cascade

Qian, Y., Zhou, L., Luk, S. T. Y., Xu, J., Li, W., Gou, H., Chen, H., Kang, W., Yu, J. Q., & Wong, C. C. (2022) · Oncogene · doi:10.1038/s41388-022-02576-4 · Cited by 16 · see citing works

Chemoproteomic Discovery of a Ritanserin-Targeted Kinase Network Mediating Apoptotic Cell Death of Lung Tumor Cells

Campbell, S., Franks, C. E., Borne, A. L., Shin, M., Zhang, L., & Hsu, K. (2018) · Molecular Pharmacology · doi:10.1124/mol.118.113001 · Cited by 15 · see citing works

Novel RAF ‐directed approaches to overcome current clinical limits and block the RAS / RAF node

Scardaci, R., Berlinska, E., Scaparone, P., Michelina, S. V., Garbo, E., Novello, S., Santamarı́a, D., & Ambrogio, C. (2024) · Molecular Oncology · doi:10.1002/1878-0261.13605 · Cited by 14 · see citing works

Daily Practice Assessment of KRAS Status in NSCLC Patients: A New Challenge for the Thoracic Pathologist Is Right around the Corner

Bontoux, C., Hofman, V., Brest, P., Ilié, M., Mograbi, B., & Hofman, P. M. (2022) · Cancers · doi:10.3390/cancers14071628 · Cited by 14 · see citing works

KRASG12C inhibitor: combing for combination

Chakraborty, A. (2020) · Biochemical Society Transactions · doi:10.1042/bst20200473 · Cited by 14 · see citing works

Recent Developments in Targeting RAS Downstream Effectors for RAS-Driven Cancer Therapy

Tatlı, Ö., & Doğanay, G. D. (2021) · Molecules · doi:10.3390/molecules26247561 · Cited by 13 · see citing works

Concurrent inhibition of ALK and SRC kinases disrupts the ALK lung tumor cell proteome

Diaz-Jimenez, A., Ramos, M., Helm, B., Chocarro, S., Frey, D. L., Agrawal, S., Somogyi, K., Klingmüller, U., Lu, J., & Sotillo, R. (2024) · Drug Resistance Updates · doi:10.1016/j.drup.2024.101081 · Cited by 13 · see citing works

Scaffold repurposing of fendiline: Identification of potent KRAS plasma membrane localization inhibitors

Wang, P., van der Hoeven, D., Ye, N., Chen, H., Liu, Z., Ma, X., Montufar‐Solis, D., Rehl, K. M., Cho, K., Thapa, S., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113381 · Cited by 13 · see citing works

Ras functional proximity proteomics establishes mTORC2 as new direct ras effector

Kovalski, J. R., Shanderson, R. L., & Khavari, P. A. (2019) · Oncotarget · doi:10.18632/oncotarget.27025 · Cited by 12 · see citing works

Non‐canonical Raf‐1/p70S6K signalling in non–small‐cell lung cancer

Qiu, Z., Ye, B., Zhao, S., Li, X., Li, L., Mo, X.-M., & Li, W. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14636 · Cited by 12 · see citing works

Molecular Radiobiology in Non-Small Cell Lung Cancer: Prognostic and Predictive Response Factors

Peinado, J., & Carnero, A. (2022) · Cancers · doi:10.3390/cancers14092202 · Cited by 9 · see citing works

Prevalence of RAF1 Aberrations in Metastatic Cancer Patients: Real-World Data

Lim, S. H., Jung, J., Hong, J. Y., Kim, S. T., Park, S. H., Park, J. O., Kim, K., & Lee, J. (2023) · Biomedicines · doi:10.3390/biomedicines11123264 · Cited by 9 · see citing works

Loss of FoxA2 accelerates neoplastic changes in the intrahepatic bile duct partly via the MAPK signaling pathway

Shen, J., Zhou, Y., Zhang, X., Peng, W. J., Peng, C., Zhou, Q., Li, C., Wen, T., & Shi, Y. (2019) · Aging · doi:10.18632/aging.102332 · Cited by 9 · see citing works

The neuroprotective effect of bisperoxovandium (pyridin-2-squaramide) in intracerebral hemorrhage

Liao, X., Lei, Y., Chen, S., Cheng, J., Zhao, D., Zhang, Z., Han, X., Zhang, Y., Liao, H., Zhuang, Y., et al. (2019) · Drug Design Development and Therapy · doi:10.2147/dddt.s204956 · Cited by 8 · see citing works

Unraveling the prevalence of various signalling pathways in non-small-cell lung cancer: a review

Nair, A. S., Jayan, A. P., Anandu, K. R., Nirmala, S. V., & Pappachen, L. K. (2023) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-023-04704-4 · Cited by 7 · see citing works

Sex disparities in non-small cell lung cancer: mechanistic insights from a cRaf transgenic disease model

Zhong, S., & Borlak, J. T. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104763 · Cited by 7 · see citing works

RAF1 kinase contributes to autophagic lysosome reformation

Toifl, S., Didusch, S., Ehrenreiter, K., Desideri, E., Dorard, C., & Baccarini, M. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115490 · Cited by 6 · see citing works

Modulation of the 14-3-3σ/C-RAF “Auto”inhibited Complex by Molecular Glues

Konstantinidou, M., Vickery, H. R., Pennings, M. A. M., Virta, J. M., Luo, S., Visser, E. J., Bannier, S. D., Srikanth, M., Cismoski, S. Z., Young, L. C., et al. (2026) · Journal of the American Chemical Society · doi:10.1021/jacs.5c12622 · Cited by 6 · see citing works

Ras proteins as therapeutic targets

Chakraborty, A., Linnane, E., & Ross, S. J. (2018) · Biochemical Society Transactions · doi:10.1042/bst20170529 · Cited by 6 · see citing works

Inhibition of lung tumorigenesis by transient reprogramming in cancer cells

Pedrosa, P., Zhang, Z., Nuñez-Quintela, V., Macías, D., Ge, J., Denholm, M., Dyas, A., Estévez‐Souto, V., Lado‐Fernández, P., Gonzalez, P., et al. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-07207-2 · Cited by 5 · see citing works

RAS: Circuitry and therapeutic targeting

Singh, G., Thakur, N., & Kumar, U. (2022) · Cellular Signalling · doi:10.1016/j.cellsig.2022.110505 · Cited by 5 · see citing works

Decoding the Role of Kinesin Superfamily Proteins in Glioma Progression

Saadh, M. J., Ghnim, Z. S., Mahdi, M. S., Chandra, M., Ballal, S., Bareja, L., Chaudhary, K., Sharma, R. K., Gupta, S., Taher, W. M., et al. (2025) · Journal of Molecular Neuroscience · doi:10.1007/s12031-025-02308-9 · Cited by 4 · see citing works

Selective inhibition of BRAF and CRAF sensitizes NF1-deficient malignant peripheral nerve sheath tumors to MEK inhibitors

Wang, J., Sarkar, A., García, N., Zhang, L., Calizo, A., Lisok, A., Campos, K., He, F., Punjaala, N., Marple, T. C., et al. (2025) · Molecular Medicine · doi:10.1186/s10020-025-01353-9 · Cited by 4 · see citing works

Establishment and Characterization of Immortalized Miniature Pig Pancreatic Cell Lines Expressing Oncogenic K-RasG12D

Yang, H.-J., Song, B., Sim, B., Jung, Y., Chae, U., Lee, D. G., Cha, J., Baek, S.-J., Lim, K. S., Choi, W. S., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228820 · Cited by 4 · see citing works

Identification of key miRNAs and their targets in peripheral blood mononuclear cells of IgA nephropathy using bioinformatics analysis

Liu, L., Yang, Y., & Yu, D. (2021) · Medicine · doi:10.1097/md.0000000000026495 · Cited by 4 · see citing works

Deciphering the universe of genetic context-dependencies using mouse models of cancer

Falcomatà, C., Bärthel, S., Schneider, G., Saur, D., & Veltkamp, C. (2019) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2019.04.002 · Cited by 3 · see citing works

Targeting small GTPases and their downstream pathways with intracellular macromolecule binders to define alternative therapeutic strategies in cancer

Sorbara, M., & Béry, N. (2021) · Biochemical Society Transactions · doi:10.1042/bst20201059 · Cited by 2 · see citing works

RAF1 as a standalone therapeutic target in KRAS-driven lung adenocarcinoma: No added efficacy from co-targeting ARAF, EGFR, or DDR1

Ovejero, L. D. L. P., Fernández-Rodríguez, A., Francoz, S., Aizpurua, G., Lomba-Riego, L., Drosten, M., Guerra, C., Musteanu, M., Barbacid, M., & García‐Alonso, S. (2026) · PLoS ONE · doi:10.1371/journal.pone.0341778 · Cited by 1 · see citing works

Disruption of the pro-oncogenic c-RAF–PDE8A complex represents a differentiated approach to treating KRAS–c-RAF dependent PDAC

Cooke, S. F., Wright, T. A., Sin, Y. Y., Ling, J., Kyurkchieva, E., Phanthaphol, N., Mcskimming, T., Herbert, K. J., Rebus, S., Biankin, A. V., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-59451-3 · Cited by 2 · see citing works

A PCR-Based Approach for Driver Mutation Analysis of EGFR, KRAS, and BRAF Genes in Lung Cancer Tissue Sections

Cavagna, R. D. O., Leal, L. F., de Paula, F. E., Berardinelli, G. N., & Reis, R. M. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1278-1_9 · Cited by 2 · see citing works

A tumour-promoting senescent secretome triggered by platinum chemotherapy exploits a targetable TGFβR1/Akt-mTOR axis in lung cancerPreprint

González‐Gualda, E., Macías, D., Morsli, S., Martín, J., Ou, H., Denholm, M., Olan, I., Hoffmann, R. J., Dane, M. A., Veroutis, D., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.08.01.502019 · Cited by 2 · see citing works

Exploiting c-RAF dependency in RAS mutant cancer: beyond catalytic activity

Cooke, S. F., & Blair, C. M. (2024) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2024.2319035 · Cited by 1 · see citing works

The repressor Capicua is a barrier to lung tumor development driven by Kras/Trp53 mutations

Ballesteros-González, I., Hernández-Navas, I., Brehey, O., Lechuga, C. G., Salmón, M., Scotece, M., Velasco-Vicente, R., Flores-Gómez, A. A., Cebriá, A., Simón-Carrasco, L., et al. (2025) · EMBO Molecular Medicine · doi:10.1038/s44321-025-00326-z · Cited by 1 · see citing works

A new hope for KRAS mutant cancers

Lujambio, A. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aas8964 · Cited by 1 · see citing works

Hsp70/Hsp90 Organizing Protein (HOP) Maintains CRAF Kinase Activity and Regulates MAPK Signaling by Enhancing Hsp90-CRAF Association

Gayen, N., Mitra, S., Roy, S., & Mandal, A. K. (2026) · Molecular and Cellular Biology · doi:10.1080/10985549.2026.2647809 · Cited by 1 · see citing works

On Target: An Intrapulmonary Transplantation Method for Modelling Lung Tumor Development in its Native Microenvironment

McDonald, J. A., Scott, L., Zuylekom, J. V., Holloway, S., Blyth, B. J., & Sutherland, K. D. (2023) · Methods in molecular biology · doi:10.1007/978-1-0716-3331-1_3 · Cited by 1 · see citing works

Cooperativity and oscillations: Regulatory mechanisms of K-Ras nanoclusters

Jurado, M., Zorzano, A., & Castaño, Ó. (2023) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2023.107455 · Cited by 1 · see citing works

Wild-type C-Raf gene dosage and dimerization drive prostate cancer metastasis

Ta, L. H., Tsai, B. L., Deng, W., Sha, J., Varuzhanyan, G., Tran, W., Wohlschlegel, J. A., Carr, J. R., & Witte, O. N. (2023) · iScience · doi:10.1016/j.isci.2023.108480 · Cited by 1 · see citing works

Oncogenic Ras/squamous cell carcinoma antigen signaling pathway activation promotes invasiveness and lymph node metastases in papillary thyroid carcinoma

Luo, D., Ying, L., Lin, S., Tan, L., Du, Z., Long, M., Zhu, Y., Peng, X., Zong, W., Mackenzie, G. G., et al. (2018) · Oncology Reports · doi:10.3892/or.2018.6895 · Cited by 1 · see citing works

c-Raf in KRas Mutant Cancers: A Moving Target

McCormick, F. P. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.01.017 · Cited by 27 · see citing works

A new hope for KRAS mutant cancers

Lujambio, A. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aas8964 · Cited by 1 · see citing works

Tumor regression and resistance mechanisms upon CDK4 and RAF1 inactivation in KRAS/P53 mutant lung adenocarcinomas

Esteban-Burgos, L., Wang, H., Nieto, P., Zheng, J., Blanco‐Aparicio, C., Varela, C., Goméz-López, G., Fernández-García, F., Sanclemente, M., Guerra, C. E., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2002520117 · Cited by 23 · see citing works

Abstract IA01: Targeting KRAS: Light at the end of the tunnel

Barbacid, M. (2023) · Molecular Cancer Research · doi:10.1158/1557-3125.ras23-ia01

RAF1 kinase activity is dispensable for KRAS/p53 mutant lung tumor progression

Sanclemente, M., Nieto, P., García‐Alonso, S., Fernández-García, F., Esteban-Burgos, L., Guerra, C. E., Drosten, M., Caleiras, E. J., Martinez-Torrecuadrada, J. L., Santamarı́a, D., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.01.008 · Cited by 34 · see citing works